Clinical access to Bedaquiline Programme for the treatment of drug-resistant tuberculosis

dc.contributor.authorConradie, F
dc.contributor.authorMeintjies, G
dc.contributor.authorHughes, J
dc.contributor.authoret al
dc.date.accessioned2015-06-04T13:12:48Z
dc.date.available2015-06-04T13:12:48Z
dc.date.issued2014-03
dc.descriptionKMen_ZA
dc.description.abstractWhile clinical disease caused by drug-sensitive Mycobacterium tuberculosis (MTB) can usually be treated successfully, clinical disease caused by drug-insensitive MTB is associated with a poorer prognosis. In December 2012, a new drug, bedaquiline, was approved by the US Food and Drug Administration. This article documents the process whereby the National Department of Health, Right to Care and Médecins Sans Frontières obtained access to this medication for South Africans who might benefit from subsequent implementation of the Clinical Access to Bedaquiline Programme.en_ZA
dc.identifier.citationConradie, F., Meintjies, G., Hughes, J., et al.Clinical access to Bedaquiline Programme for the treatment of drug-resistant tuberculosis. SAMJ;104(3):164-166en_ZA
dc.identifier.urihttp://hdl.handle.net/10539/17955
dc.language.isoenen_ZA
dc.subjectTuberculosis, Multidrug-Resistanten_ZA
dc.subjectBedaquilineen_ZA
dc.titleClinical access to Bedaquiline Programme for the treatment of drug-resistant tuberculosisen_ZA
dc.typeArticleen_ZA
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Clinical access to Bedaquiline Programme for the treatment of drug-resistant tuberculosis.pdf
Size:
89.41 KB
Format:
Adobe Portable Document Format
Description:
License bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Collections